BioCentury | Aug 31, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...Milo Biotechnology LLC (Cleveland, Ohio) is conducting a Phase I/II trial of gene therapy AAV1-FS344 (AAV1-FS...
BioCentury | Aug 30, 2018
Clinical News

Pfizer ends Phase II trials of DMD candidate

...Milo Biotechnology LLC (Cleveland, Ohio) is conducting a Phase I/II trial of gene therapy AAV1-FS344 (AAV1-FS...
BioCentury | Feb 2, 2018
Product Development

AA Viral meme

Gene therapy pioneer James Wilson’s revelation of two new types of toxicity in animals receiving high systemic doses of adeno-associated viral vectors is unlikely to herald a major disruption of the AAV space, though it...
BioCentury | Oct 27, 2014
Clinical News

AAV1-FS344: Phase I/IIa data

A dose-escalation Phase I/IIa trial in 6 patients with Becker muscular dystrophy showed that AAV1-FS344 given by direct bilateral intramuscular quadriceps injections improved 6MWT in 4 patients. In cohort 1 (n=3), 3*1011 vg/kg/leg AAV1-FS344 improved...
BioCentury | Dec 17, 2012
Clinical News

AAV1-FS344 regulatory update

Milo said FDA granted Orphan Drug designation to AAV1-FS344 to treat Becker and Duchenne muscular dystrophy. The adeno-associated virus (AAV) vector encoding follistatin is in a Phase I/II trial for Becker muscular dystrophy and inclusion...
BioCentury | Aug 6, 2012
Emerging Company Profile

Milo: Dismissing dystrophin

...could avoid immune reactions that have scuttled previous gene therapies. The company's only candidate is AAV1-FS...
...the population has such antibodies at high enough levels to cause problems. Patients in the AAV1-FS...
...are also receiving immunosuppressants. Preclinical studies conducted at Nationwide showed that a single dose of AAV1-FS...
BioCentury | Feb 17, 2012
Company News

Newco Milo debuts to develop muscular dystrophy treatment

...Ohio) raised $250,000 in seed funding from the not-for-profit JumpStart Inc. The newco's lead product, AAV1-FS...
Items per page:
1 - 7 of 7